New Technology– category –
-
LNP Automation Platform: MIT’s RNA Therapy Design System
BIOENGINEER.ORG USA Overview Researchers at MIT have developed an automated platform for manufacturing lipid nanoparticles (LNPs) with precise control over size and shape. By integrating a two-step mixing process with real-time measureme... -
Enspryng: FDA approval for Roche’s first at-home TED treatment
Roche (Press Release) USA Overview The FDA has approved Roche’s Enspryng (satralizumab) as the first and only at-home subcutaneous treatment for thyroid eye disease (TED). Based on Phase III SatraGO trials, the IL-6R inhibitor significan... -
Temab-A: AbbVie’s c-Met ADC Breakthrough Designations for CRC and NSCLC
Cure Today / PR Newswire USA Overview The FDA has granted two Breakthrough Therapy Designations to AbbVie's c-Met targeting antibody-drug conjugate (ADC), Temab-A, for metastatic colorectal cancer and non-small cell lung cancer. These de... -
Enhertu: AstraZeneca and Daiichi Sankyo China approval timeline
Daiichi Sankyo Japan Overview Enhertu® (trastuzumab deruxtecan), the HER2-targeted antibody-drug conjugate (ADC) co-developed by Daiichi Sankyo and AstraZeneca, has been approved in China for adjuvant treatment of HER2-positive early bre... -
Ubamatamab: Regeneron’s MUC16×CD3 antibody 73% response specs
Pharmacally USA Overview Regeneron Pharmaceuticals announced initial clinical results for its investigational MUC16×CD3 bispecific antibody, Ubamatamab, in patients with advanced low-grade serous ovarian cancer (LGSOC). Data from the ong... -
GrowGen framework: Molecular generation specs via deep learning
Frontiers International Overview This research introduces the 'GrowGen' framework, combining a decoder-only Transformer with reinforcement learning for stable, property-conditioned molecular generation. GrowGen uniquely features property... -
AI Chemists: ETH Zurich and Roche drug synthesis roadmap 2026
Bioengineer.org Switzerland Overview A research team from ETH Zurich and Roche Pharma Research and Early Development has unveiled a closed-loop workflow that predicts chemical reactions with high accuracy, even with limited experimental ... -
TEV-‘749: Teva’s subcutaneous olanzapine Phase 3 safety specs
Psychiatric Times USA Overview Teva Pharmaceutical Industries announced positive post-hoc data from its Phase 3 SOLARIS study of subcutaneous olanzapine (TEV-'749), confirming consistent long-term efficacy and safety for schizophrenia. C... -
Ionis Ulefnersen: P3 results for FUS-ALS and RNA specs 2026
TradingView USA Overview Ionis Pharmaceuticals announced that its FUS-ALS treatment, ulefnersen, met its primary endpoint in the Phase III FUSION trial, signaling a potential breakthrough for this devastating neurodegenerative disease. C... -
Dapis Cyanobacteria: Dolastatin 15 anticancer source explained
UF Health USA Overview University of Florida College of Pharmacy researchers identified the marine cyanobacterial genus Dapis as the natural source of dolastatin 15, a potent anticancer compound. This research marks the first genomic cha...
